Full Press Release Details
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis – Zai Lab Limited.
ZLAB
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis – Zai Lab Limited
Key Takeaway: Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis – Zai Lab Limited
Price reaction · baseline $37.69 (2022-07-12 close) · hit after-hours · clean, no other ZLAB news in the window
day 0 close
+0.9%
day 1
-0.1%
day 3 · peak
+10.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.2%
average across 15 past catalysts
Cash runway
~28 mo
Low dilution risk
Lead asset
ZL-1310
Phase 3 · Small-cell Lung Cancer